Skip to main content
SchizophreniaMental healthChildren's healthDrugPhase 3

What this study is

The purpose of this study is to evaluate the long-term safety and tolerability of Xanomeline and Trospium Chloride for the treatment of psychiatric disorders in children and adolescents

What's being tested

  • KarXT

    Intervention · DRUG

  • KarX-EC

    Intervention · DRUG

Both interventions

Specified dose on specified days

Study details

Official title
A Phase 3 Multicenter, Open-label Study to Assess the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride in Children and Adolescents With Psychiatric Disorders
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Conditions
Schizophrenia · Autism-Related Irritability
Enrolling
400 people
Starts
2026-04-07
Est. completion
2030-03-08
Design
Open-label, non-randomized, single group, Phase 3
Record
View on ClinicalTrials.gov ↗